胆甾烷-3,7,12,26,27-五醇 | 2952-70-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 胆甾烷-3,7,12,26,27-五醇
• 英文名称: 5alpha-Cyprinol
• 英文别名: (3R,5R,7R,8R,9S,10S,12S,13R,14S,17R)-17-[(2R)-7-hydroxy-6-(hydroxymethyl)heptan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol
• CAS: 2952-70-7
• 化学式: C₂₇H₄₈O₅
• 分子量: 452.7
• InChiKey: JNMALBXXJSWZQY-BBBUMGABSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  101
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• BILE ALCOHOL AND DRUG CONTAINING THE SAME AS ACTIVE INGREDIENT
  申请人：TSUMURA CO., LTD.

  公开号：EP0489933A1

  公开（公告）日：1992-06-17

  A novel bile alcohol of general formula (I), having an efficacious physiological activity and being specified in the configurations of particularly the 20-, 24- and 25-positions; formula (I) wherein one of the groups R₁ and R₂ represents a group of formula (A) or (B) while the other represents -OH or -H; R₃ and R₄ represent each -CH₂OH, -CH₃ or -CH₂OSO₃Na; or alternatively R₂ and R₃ are combined together to represent -OCH₂-, R₂ and R₄ are combined together to represent -OCH₂-, or R₃ and R₄ are combined together to represent -CH₂OCH₂-; provided that R₃ and R₄ do not represent -CH₃ at the same time and that R₁ represents -OH or -H and R₂ represents the group of formula (A) or (B) when R₃ and R₄ represent -CH₂OH at the same time. A drug containing the bile alcohol, including those wherein R₃ and R₄ in the above formula (I) represent each -H, -CH₂OH, -CH₃ or -CH₂OSO₃Na (except for the case where both R₃ and R₄ represent -H at the same time), and 3α 7α, 12α, 24-tetrahydroxy-5α- or -5β-cholane is efficacious as a cerebral function protective agent, cholagogue, cell activator, microcirculation improver, antiarteriosclerotic agent, antihyperlipemia drug, hepatic function improver, anti-inflammatory drug, antithrombotic drug and hypertensive.

  通式（I）的新胆醇具有有效的生理活性，特别是在20、24和25位的构型中进行了指定。其中，R₁和R₂中的一个代表公式（A）或（B）的基团，而另一个代表-OH或-H；R₃和R₄分别代表-CH₂OH、-CH₃或-CH₂OSO₃Na；或者R₂和R₃结合在一起代表-OCH₂-，R₂和R₄结合在一起代表-OCH₂-，或者R₃和R₄结合在一起代表-CH₂OCH₂-；前提是R₃和R₄不能同时表示-CH₃，而且当R₃和R₄同时表示-CH₂OH时，R₁表示-OH或-H，R₂表示公式（A）或（B）的基团。含有胆醇的药物，包括上述公式（I）中R₃和R₄分别表示-H、-CH₂OH、-CH₃或-CH₂OSO₃Na的药物（除了R₃和R₄同时表示-H的情况），以及3α 7α，12α，24-四羟基-5α-或-5β-胆烷作为脑功能保护剂、胆汁促进剂、细胞活化剂、微循环改善剂、抗动脉硬化药、降脂药、肝功能改善剂、抗炎药、抗血栓药和降压药具有有效性。
• METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER
  申请人：Haggerty Timothy J.

  公开号：US20140335050A1

  公开（公告）日：2014-11-13

  The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.